NASDAQ · Financial Statements

Bioventus Inc. (BVS) Financial Statements

$14.96 NASDAQ: BVS Market Cap $1.02B

Bioventus Inc. most recently reported annual revenue of $568.0M, net profit of $23.0M. Revenue grew at an average annual rate of 12.1% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Bioventus Inc.: Revenue rose from $275.0M in 2016 to $568.0M in 2025, a change of +106.5% over 9 years; net profit was positive in 4 of 12 reported years; operating margin moved from 5.4% to 10.3%, a shift of +4.9 percentage points; the most recent year shows net profit of $23.0M.

Income Statement — 12 Years (USD millions)

Metric201420152016201720182019202020212022202320242025
Revenue——$275.0M$292.0M$319.0M$340.0M$321.0M$431.0M$512.0M$512.0M$573.0M$568.0M
Operating Expenses——$260.0M$265.0M$294.0M$309.0M$300.0M$419.0M$679.0M$594.0M$585.0M$510.0M
Operating Profit——$15.0M$27.0M$26.0M$31.0M$21.0M$12.0M$-167.0M$-82.0M$-12.0M$59.0M
Operating Margin0.0%0.0%5.4%9.3%8.0%9.2%6.6%2.8%-32.7%-15.9%-2.1%10.3%
Other Income——$-21.0M$-18.0M$-19.0M$-22.0M$-5.0M$-3.0M$-22.0M$-39.0M$-37.0M$-33.0M
Interest$0$0$16.0M$19.0M$19.0M$22.0M$10.0M$1.0M$12.0M$41.0M$39.0M$26.0M
Depreciation$29.0M$33.0M$34.0M$32.0M$29.0M$30.0M$29.0M$35.0M$55.0M$57.0M$50.0M$47.0M
Profit Before Tax——$-6.0M$9.0M$6.0M$10.0M$16.0M$9.0M$-189.0M$-121.0M$-49.0M$26.0M
Tax——$-19.3M$-9.1M$27.3M$16.3M$7.5M$-20.7M$23.5M$-70,000$10.8M$-6.1M
Net Profit——$-18.0M$-2.0M$-12.0M$7.0M$16.0M$19.0M$-159.0M$-156.0M$-34.0M$23.0M
EPS$0.00$0.00$-0.41$-0.13$-0.22$0.12$0.44$0.43$-2.59$-2.49$-0.52$0.33
Dividend Payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricSep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26
Revenue$121.0M$135.0M$129.0M$151.0M$139.0M$154.0M$124.0M$148.0M$139.0M$158.0M$132.0M$153.0M
Operating Expenses$118.0M$134.0M$125.0M$183.0M$135.0M$146.0M$119.0M$129.0M$127.0M$136.0M$123.0M$134.0M
Operating Profit$2.0M$1.0M$5.0M$-31.0M$4.0M$8.0M$5.0M$19.0M$12.0M$22.0M$9.0M$19.0M
Operating Margin2.0%0.9%3.8%-20.8%2.9%5.2%4.0%12.6%8.7%13.8%6.7%12.5%
Interest$10.0M$10.0M$10.0M$10.0M$10.0M$9.0M$8.0M$7.0M$6.0M$5.0M$4.0M$4.0M
Profit Before Tax$-8.0M$-8.0M$-5.0M$-42.0M$-5.0M$0$-3.0M$10.0M$5.0M$14.0M$5.0M$15.0M
Tax$-7.3M$8.9M$-16.6M$17.7M$-12.2M$237.1M$2.8M$10.1M$14.2M$-22.4M$12.6M$-136.5M
Net Profit$-7.0M$-6.0M$-5.0M$-26.0M$-5.0M$0$-3.0M$7.0M$3.0M$15.0M$3.0M$33.0M
EPS$-0.12$-0.10$-0.08$-0.37$-0.07$0.00$-0.04$0.11$0.05$0.21$0.04$0.47

Over the 12 years reported for Bioventus Inc., borrowings increased from $171.0M in 2014 to $311.0M in 2025, cash stood at $51.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 1.71 times.

Balance Sheet — 12 Years (USD millions)

Metric201420152016201720182019202020212022202320242025
Total Assets$430.0M$487.0M——$443.0M$472.0M$494.0M$1.2B$1.4B$811.0M$728.0M$684.0M
Current Assets$95.0M$99.0M——$148.0M$183.0M$212.0M$263.0M$273.0M$268.0M$276.0M$273.0M
Cash$16.0M$5.0M——$43.0M$65.0M$87.0M$44.0M$30.0M$37.0M$42.0M$51.0M
Inventory$27.0M$35.0M——$27.0M$27.0M$29.0M$62.0M$85.0M$91.0M$92.0M$82.0M
Receivables$47.0M$55.0M——$73.0M$85.0M$88.0M$125.0M$136.0M$123.0M$127.0M$128.0M
Fixed Assets$10.0M$10.0M——$5.0M$20.0M$22.0M$40.0M$44.0M$50.0M$34.0M$27.0M
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0$0$0
Investments$0$0$0$0$3.0M$3.0M$19.0M$29.0M$3.0M$0$0$0
Other Assets$50.0M$59.0M——$50.0M$50.0M$50.0M$148.0M$7.0M$7.0M$7.0M$7.0M
Total Liabilities$253.0M$295.0M——$297.0M$327.0M$350.0M$692.0M$960.0M$590.0M$542.0M$455.0M
Current Liabilities$52.0M$88.0M——$65.0M$89.0M$123.0M$181.0M$304.0M$175.0M$210.0M$160.0M
Borrowings$171.0M$197.0M$0$0$195.0M$198.0M$188.0M$358.0M$418.0M$395.0M$336.0M$311.0M
Other Liabilities$82.0M$99.0M——$103.0M$129.0M$162.0M$334.0M$542.0M$195.0M$207.0M$144.0M
Equity$113.0M$113.0M——$285.0M$285.0M$285.0M$0$0$0$0$0
Reserves$177.0M$192.0M——$145.0M$143.0M$142.0M$459.0M$325.0M$174.0M$148.0M$184.0M

For Bioventus Inc., operating cash flow was positive in 9 of 12 reported years; free cash flow in the latest year was $71.0M; free cash flow was positive in 8 of 12 years; financing activities used $21.0M in the latest year, which covers debt repayment, dividends and buybacks.

Cash Flow Statement — 12 Years (USD millions)

Metric201420152016201720182019202020212022202320242025
Operating Cash Flow$15.0M$19.0M——$45.0M$41.0M$72.0M$23.0M$-14.0M$15.0M$39.0M$74.0M
Investing Cash Flow$-52.0M$-68.0M——$-12.0M$-16.0M$-41.0M$-305.0M$-118.0M$8.0M$22.0M$-6.0M
Financing Cash Flow$0$-17.0M——$0$0$0$-2.0M$-3.0M$-4.0M$3.0M$-21.0M
Net Cash Flow$-24.0M$-11.0M——$26.0M$22.0M$22.0M$12.0M$-67.0M$5.0M$5.0M$10.0M
Free Cash Flow$-6.0M$11.0M$0$0$39.0M$32.0M$51.0M$2.0M$-15.0M$8.0M$38.0M$71.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA12.40
FCF Yield10.28%
Quick Ratio1.17
Interest Coverage3.11
Return 1Y77.43%
Return 3Y222.47%
Return 5Y-28.42%

Bioventus Inc. (BVS) financials — frequently asked questions

What is Bioventus Inc.'s annual revenue?

Bioventus Inc. (BVS) reported annual revenue of $568.0M in its most recent fiscal year.

What is Bioventus Inc.'s net profit?

Bioventus Inc. (BVS) reported net profit of $23.0M in its most recent fiscal year.

What is BVS EV/EBITDA?

Bioventus Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is 12.40.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
BVS Overview BVS Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.